NewLink Genetics Corporation (NLNK) saw its loss narrow to $15.54 million, or $0.54 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $15.91 million, or $0.55 a share.

Revenue during the quarter grew 7.99 percent to $15.34 million from $14.21 million in the previous year period.

Operating loss for the quarter was $16.87 million, compared with an operating loss of $15.68 million in the previous year period.

"We continue to focus our clinical developmental efforts targeting the IDO pathway. We have two distinct IDO pathway inhibitors advancing in the clinic, GDC-0919 with our partner Genentech and indoximod, our proprietary IDO pathway inhibitor," said Charles J. Link, Jr. MD, chairman, chief executive officer and chief scientific officer. "We are also encouraged by recent clinical data that increasingly validate the IDO pathway as an important target in immuno-oncology."

Days sales outstanding went down to 62 days for the quarter compared with 99 days for the same period last year.

Debt comes down significantly
NewLink Genetics Corporation has recorded a decline in total debt over the last one year. It stood at $0.33 million as on Sep. 30, 2016, down 66.33 percent or $0.66 million from $0.99 million on Sep. 30, 2015. Total debt was 0.18 percent of total assets as on Sep. 30, 2016, compared with 0.44 percent on Sep. 30, 2015.